Valneva Advances New Vaccines Agenda With Top-Line Phase III Chikungunya Data
Final Results Within The Next Six Months
Executive Summary
France’s Valneva has announced positive top-line Phase III data for its investigational chikungunya vaccine, and the NASDAQ- and Euronext-listed company looks set to launch the product next year.
You may also be interested in...
Valneva's COVID-19 Vaccine Hopes Almost Over Before They Start
Rather than terminating a deal for the French biotech's VLA2001 vaccine, the European Commission has put in a tiny order of 1.25 million doses which could bring the curtain down on Valneva's COVID-19 programs.
Valneva’s Lyme Disease Jab Program Gets Pfizer Cash Boost
Pfizer will invest in partner Valneva’s late-stage Lyme disease jab program, providing much-needed financial support to the French firm which has suffered COVID-19 vaccine sales setbacks.
Valneva Bounces Back From UK Snub With EU COVID-19 Vaccine Deal
The European Commission has approved a purchase deal for Valneva’s COVID-19 vaccine candidate just months after the UK scrapped its own deal with the firm.